Abstract Therapeutic antibody IgG1 has two N-linked oligosaccharide chains bound to the Fc region. The oligosaccharides are of the complex biantennary type, composed of a trimannosyl core structure with the presence or absence of core fucose, bisecting N-acetylglucosamine (GlcNAc), galactose, and terminal sialic acid, which gives rise to structural heterogeneity. Both human serum IgG and therapeutic antibodies are well known to be heavily fucosylated. Recently, antibody-dependent cellular cytotoxicity (ADCC), a lytic attack on antibodytargeted cells, has been found to be one of the critical effector functions responsible for the clinical efficacy of therapeutic antibodies such as anti-CD20 IgG1 rituximab (Rituxan 1 ) and anti-Her2/neu IgG1 trastuzumab (Herceptin 1 ). ADCC is triggered upon the binding of lymphocyte receptors (FccRs) to the antibody Fc region. The activity is dependent on the amount of fucose attached to the innermost GlcNAc of N-linked Fc oligosaccharide via an a-1,6-linkage, and is dramatically enhanced by a reduction in fucose. Non-fucosylated therapeutic antibodies show more potent efficacy than their fucosylated counterparts both in vitro and in vivo, and are not likely to be immunogenic because their carbohydrate structures are a normal component of natural human serum IgG. Thus, the application of non-fucosylated antibodies is expected to be a powerful and elegant approach to the design of the next generation therapeutic antibodies with improved efficacy. In this review, we discuss the importance of the oligosaccharides attached to the Fc region of therapeutic antibodies, especially regarding the inhibitory effect of fucosylated therapeutic antibodies on the efficacy of non-fucosylated counterparts in one medical agent. The impact of completely non-fucosylated therapeutic antibodies on therapeutic fields will be also discussed.
Introduction
Most of the current therapeutic antibodies that have been licensed and developed as medical agents are human IgG1 isotype including mouse/human chimeric, humanized and human IgG1. Human IgG1 is a glycoprotein bearing two N-linked biantennary complex-type oligosaccharides bound to the antibody constant region (Fc) , in which the majority of the oligosaccharides are core-fucosylated (Mizuochi et al. 1982; Harada et al. 1987; Rademacher et al. 1988; Jefferis 2001) , and it exercises effector functions of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) through the interaction of the Fc with either leukocytes receptors (FccRs) or complement. Some therapeutic antibodies can mediate direct apoptosis to the target cells as well. The efficacy of therapeutic antibodies results from specificity for the target antigen and the antibody effector functions, which are activated by the formation of immune complexes (Fig. 1) . Recently, therapeutic antibodies have been shown to improve overall survival as well as time to disease progression in a variety of human malignancies such as breast, colon and haematological cancers (de Bono and Rowinsky 2002; Forero and Lobuglio 2003; Grillo-Lopez 2003; Vogel and Franco 2003) and genetic analysis of FccR polymorphisms of cancer patients has clearly demonstrated that ADCC is one of the major anti-neoplasm mechanism responsible for clinical efficacy (Cartron et al. 2002; Anolik et al. 2003; Weng and Levy 2003; Dall'Ozzo et al. 2004; Gennari et al. 2004 ). The common features of antibody therapeutics, representing as high specificity to the target, long stability in blood, and high physiological functions induced effective clinical efficacy, are just about to be the features necessary for molecular-target based medicines. Thus, therapeutic antibodies now comprise the majority of recombinant proteins currently used in the clinic. A number of trials using therapeutic antibodies are ongoing, including more than 200 preclinical and 150 clinical studies (Reichert et al. 2005) and 17 types of recombinant monoclonal therapeutic antibodies have been approved in the U.S., and these agents represent a major new class of drugs (Table 1) . It is generally expected that the indications for the use of therapeutic antibodies will be dramatically expanded in near future. Worldwide sales of total therapeutic antibodies have already exceeded 10 billion dollars in 2004 (Baker 2005) .
Current feature of therapeutic antibodies
Although antibody therapeutics are currently recognized as new medicines that confer great benefits to patients suffering from various obstinate diseases, we also realize that these agents yield a serious issue of medical economy, so called ''economical toxicity''. A common feature of therapeutic antibodies used for cancer treatment is that their anti-tumor efficacy requires high serum concentrations and continued therapy for several months. The treatment cycles thereby consume several grams of therapeutic antibody, resulting in a significant amount of drug needed and very high costs (Berinstein et al. 1998; Baselga and Albanell 2001; Goldenberg 1999) . In fact, administration of a high dose (2-8 mg kg -1 ) of either anti-CD20 IgG1 rituximab (Rituxan 1 ) or anti-Her2/ neu IgG1 trastuzumab (Herceptin 1 ) is required to keep the effective serum concentration of over 10 lg mL -1 , which is more than 100-fold high administrated dose of cytokine therapy such as erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) regimens. The drug cost of one cycle medical treatment with such therapeutic antibodies amounts to being over 20 thousand dollars. This is one of the reasons why annual sales of rituximab and trastuzumab have exceed and almost reached 2 billion dollars, respectively, although the population of either non-Hodgkin's lymphoma or breast cancer patients is limited; both patient groups are not major in whole cancer patients. As mentioned above, the indication of therapeutic antibodies will be (d), mannose (h), bisecting GlcNAc ( ), fucose ( ) galactose ( ), sialic acid (m)) attached to the CH 2 domains of the Fc affect the cellular cytotoxicity of ADCC more expanded in near future, and the economical situation of antibody therapy will soon no longer be viable, i.e., will be at risk of collapse. Moreover, there still remains the need to improve the efficacy of therapeutic antibodies such that they can be used to achieve not only remission, but also complete recovery from disease; many of the currently approved therapeutic antibodies remain unable to induce more than remission. Currently, numerous efforts to improve the efficacy of therapeutic antibodies are underway. These include the introduction of amino acid mutations in the Fc region (Shields et al. 2001; Lazar et al. 2006 ) and the co-administration of CpG as an adjuvant (Jahrsdorfer and Weiner 2003; van Ojik et al. 2003) or that of cytokines such as IL-2 (Friedberg et al. 2002) and GM-CSF (Stockmeyer et al. 2001) . Among these efforts, the modification of N-linked Fc oligosaccharides, especially core-fucose removal, has been of note as a key of next generation therapeutic antibodies with improved efficacy (Shields et al. 2002; Shinkawa et al. 2003; Yamane-Ohnuki et al. 2004; Mori et al. 2004; Okazaki et al. 2004; Niwa et al. 2004a Niwa et al. , b, 2005a Niwa et al. , 2005b Natsume 2005; Jefferis 2005; Iida et al. 2006; Kanda et al. 2006; Satoh et al. 2006) .
Human serum IgG inhibits therapeutic antibodyinduced ADCC
We should note that there is a huge discrepancy between the potency of therapeutic antibodies in vitro and in vivo, in terms of dosing therapeutic antibodies, especially anti-cancer antibodies. Cancer patients treated with therapeutic antibodies typically need to receive weekly doses of several hundred milligrams over several months for keeping the effective serum concentration of more than 10 lg mL -1 (Baselga and Albanell 2001; Berinstein et al. 1998; Goldenberg 1999) . On the contrary, the maximal in vitro cellular cytotoxicity by ADCC of these therapeutic antibodies can be achieved at antibody concentrations of less than 10 ng mL -1 , which is several orders of magnitude below the targeted serum concentrations (Lewis et al. 1993; Sliwkowski et al. 1999 ). This discrepancy, the low in vivo efficacy of therapeutic antibodies in contrast to the high in vitro ADCC, Preithner et al. 2006) . Human serum IgG dose not affect antigen binding by therapeutic antibodies however significantly impairs interaction of the antibodies with FccRIIIa, and induce the inhibition of the ADCC of therapeutic antibodies. This phenomenon leads to the elucidation of necessity of the use of high doses in the clinical treatment, and also elucidates the molecular mechanism for the enhanced efficacy of non-fucosylated therapeutic antibodies in humans. Non-fucosylated therapeutic antibodies have much higher binding affinity for FccRIIIa than fucosylated human serum IgG, which is a preferable character to conquer the interference by human plasma IgG Satoh et al. 2006) . Therefore, non-fucosylated therapeutic antibodies can evade the inhibitory effect of human plasma IgG on ADCC through their high FccRIIIa bonding.
Fucosylated therapeutic antibodies spoil the nonfucosylated antibody-induced ADCC
More importantly, the enhanced ADCC of nonfucosylated therapeutic antibodies against a specific antigen has been shown to be inhibited in a dosedependent manner by fucosylated antibodies against the same antigen in the case of both rituximab and trastuzumab in vitro and ex vivo Satoh et al. 2006) . Non-fucosylated therapeutic antibodies existing in the antibody mixtures, composed of non-fucosylated and fucosylated forms, do not exhibit activity equivalent to that of equal amounts of non-fucosylated therapeutic antibodies alone. This phenomenon reflects the fact that the maximum efficacy of both in vitro and ex vivo ADCCs of fucosylated therapeutic antibodies never reaches the level as high as that by non-fucosylated therapeutic antibodies, even when high doses of the fucosylated antibodies are employed. One of the major mechanisms for the inhibitory effect of fucosylated therapeutic antibodies on the ADCC activity of non-fucosylated counterparts is considered to be through the competition of the two antibodies for the antigens on target cells. Therapeutic antibodies have the same antigen binding ability irrespectively of core-fucosylation, and the density of the nonfucosylated antibodies binding on the target cells is thus reduced by fucosylated antibody occupation, which yields a similar effect to shed the target antigens from capture by the therapeutic agent possessing high ADCC activity, i.e., non-fucosylated therapeutic antibodies, even in human plasma. To overcome the interference of human plasma IgG, the target tumor cells need to be coated with therapeutic antibodies possessing higher binding affinity to FccRIIIa than human plasma IgG. Hence, therapeutic antibodies consisting of only the non-fucosylated human IgG1 form (i.e., not including any of its fucosylated counterparts) is thought to be ideal.
Manufacturing of non-fucosylated therapeutic antibodies
All therapeutic antibodies currently licensed on the market are produced in rodent mammalian cell lines such as Chinese hamster ovary (CHO), mouse myeloma NS0 and SP2/0 and mouse hybridoma, and almost all of molecules produced by these cell lines have core-fucosylation in the Fc oligosaccharides (Schenerman et al. 1999; Kamoda et al. 2004) which means that ADCC of the products is unfortunately far from optimal. These cell lines retain the intrinsic a-1,6-fucosyltransferase (FUT8) enzyme activity responsible for the core-fucosylation of the Fc oligosaccharides. FUT8 catalyzes the transfer of fucose from GDP-fucose to the innermost GlcNAc in an a-1,6 linkage (Uozumi et al. 1996) , and complete and irreversible inactivation of FUT8 function in antibody producing cells is essential to manufacture non-fucosylated therapeutic antibodies. A production process in which the core-fucosylation levels of the products vary depending on culture conditions should introduce severe clinical issues, and is therefore unacceptable from a practical industrial standpoint. Robust stable production of completely non-fucosylated therapeutic antibodies in a fixed quality has been achieved by the generation of a unique host cell line, in which the endogenous FUT8 gene is knocked out Kanda et al. 2006 ). FUT8-knockout CHO/DG44 cells exhibit a morphology, growth kinetics, and productivity similar to those of the parent cells, and enable to stably produce non-fucosylated therapeutic antibodies with fixed quality and consistent ADCC activity of the ingredients in fed-batch serum-free cultures using bioreactors commonly employed in pharmaceutical industry. Thus, the application of non-fucosylated antibodies is expected to be a promising approach as a next-generation of therapeutic antibodies with improved efficacy even when administrated in low doses in humans in vivo . Clinical trials using non-fucosylated antibody therapeutics are currently underway.
